Researchers conducted the UP-TAINED study to assess the effectiveness and safety of upadacitinib for over 2 years, with patients with moderate to severe AD receiving either 15 mg or 30 mg once daily.

Most of what AI chatbots know about the world comes from devouring massive amounts of text from the internet—with all its ...

Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied. 2,3 As more people live fast-paced ...

Mepolizumab significantly reduced asthma exacerbations and oral corticosteroid use in patients with SEA, with or without CRSwNP, in a real-world setting. Improvements in lung function and asthma ...

Cardiovascular disease still claims more lives than any other illness, and many adults living with obesity or type 2 diabetes carry a heavy risk of heart attack and stroke. Two medications, ...

Perhaps to the surprise of their creators, large language models have become confidants, therapists, and, for some, intimate ...

Brentuximab vedotin with CHP is effective and safe for first-line PTCL treatment, achieving an 80% overall response rate. Median progression-free survival was 39.7 months, with a 1-year overall ...

Please provide your email address to receive an email when new articles are posted on . Patient adherence to topical glaucoma treatment remains an obstacle, with poorer adherence seen as patients are ...

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...

Lutathera showed antitumor activity in metastatic BP-NETs, with partial responses in 17% of patients and stable disease in 30%. The study reported a median progression-free survival of 10.8 months and ...